Assembly Biosciences, INC. (ASMB) — 10-Q Filings

10-Q Filings (6)

• Assembly Bio Narrows Q3 Loss, Secures $175M Funding Round — Nov 10, 2025 Risk: medium
  ASSEMBLY BIOSCIENCES, INC. reported a net loss of $9.196 million for the three months ended September 30, 2025, a slight improvement from the $9.613 million net
• Assembly Bio Narrows Q2 Loss to $28.7M Amid R&D Streamlining — Aug 6, 2025 Risk: high
  ASSEMBLY BIOSCIENCES, INC. reported a net loss of $28.7 million for the three months ended June 30, 2025, a decrease from the $30.1 million net loss for the sam
• Assembly Biosciences Files Q1 2025 10-Q — May 8, 2025 Risk: medium
  Assembly Biosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business
• Assembly Biosciences Files Q3 2024 10-Q — Nov 7, 2024 Risk: medium
  Assembly Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details the company's financial position and operations, includin
• Assembly Biosciences Q2 2024: Cash Down, Arbutus Deal Details — Aug 8, 2024 Risk: medium
  Assembly Biosciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported cash and cash equivalents of $200.6 million as of June 30, 2
• Assembly Biosciences, Inc. Files 10-Q for Period Ending March 31, 2024 — May 8, 2024 Risk:
  ASSEMBLY BIOSCIENCES, INC. (ASMB) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Assembly Biosciences, Inc. filed a 10-Q report for the period end

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX